Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis

Archives of Dermatology

Volumn 148, Issue 6, 2012, Pages 747-752

  Minkis, Kira ^a   Aksentijevich, Ivona ^b   Goldbach Mansky, Raphaela ^c   Magro, Cynthia ^a   Scott, Rachelle ^a   Davis, Jessica G ^a   Sardana, Niti ^a   Herzog, Ronit ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CHROMOSOME 2; CLINICAL FEATURE; DEFICIENCY OF INTERLEUKIN 1 RECEPTOR ANTAGONIST; DRUG DOSE REDUCTION; ETHNIC GROUP; GENE; GENE DELETION; GENETIC SCREENING; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IL1RN GENE; INFANT; INFANTILE PUSTULAR PSORIASIS; INFANTILE PUSTULOSIS; INFLAMMATION; MALE; PRIORITY JOURNAL; PUERTO RICAN; PUSTULAR PSORIASIS; PUSTULOSIS; SKIN BIOPSY; SKIN EXAMINATION; SYSTEMIC DISEASE;

ANTIRHEUMATIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HEREDITARY AUTOINFLAMMATORY DISEASES; HISPANIC AMERICANS; HUMANS; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PSORIASIS; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84862689250     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.3208     Document Type: Article

References (30)

1. Mengesha YM, Bennett ML. Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol. 2002;3(6):389-400. (Pubitemid 34879432)
2. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360 (23):2426-2437.
3. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009;360(23):2438-2444.
4. Stenerson M, Dufendach K, Aksentijevich I, Brady J, Austin J, Reed AM. The first case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1-receptor antagonist. Arthritis Rheum. 2011;63(12):4018-4022.
5. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci. 2009;1182:111-123.
6. Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258-267.
7. Nakajima A, Matsuki T, Komine M, et al. TNF, but not IL-6 and IL-17, is crucial for the development of T cell-independent psoriasis-like dermatitis in Il1rn-/-mice. J Immunol. 2010;185(3):1887-1893.
8. Lamacchia C, Palmer G, Seemayer CA, Talabot-Ayer D, Gabay C. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum. 2010;62(2): 452-462.
9. Isoda K, Matsuki T, Kondo H, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c mice. Arterioscler Thromb Vasc Biol. 2010;30(4):708-715.
10. Koenders MI, Devesa I, Marijnissen RJ, et al. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum. 2008;58(11):3461-3470.
11. Ganaiem M, AbuElhija M, Lunenfeld E, et al. Effect of interleukin-1 receptor antagonist gene deletion on male mouse fertility. Endocrinology. 2009;150(1): 295-303.
12. Kagari T, Tanaka D, Doi H, Iwakura Y, Shimozato T. Anti-type II collagen antibody accelerates arthritis via CXCR2-expressing cells in IL-1 receptor antagonist-deficient mice. Eur J Immunol. 2007;37(10):2753-2763. (Pubitemid 47578294)
13. Cho ML, Kang JW, Moon YM, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol. 2006;176(9):5652-5661.
14. Ishida Y, Kondo T, Kimura A, Matsushima K, Mukaida N. Absence of IL-1 receptor antagonist impaired wound healing along with aberrant NF-kappaB activation and a reciprocal suppression of TGF-β signal pathway. J Immunol. 2006; 176(9):5598-5606.
15. Kotani M, Hirata K, Ogawa S, et al. CD28-dependent differentiation into the effector/memory phenotype is essential for induction of arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum. 2006;54(2):473-481. (Pubitemid 43228621)
16. Zhou F, He X, Iwakura Y, Horai R, Stuart JM. Arthritis in mice that are deficient in interleukin-1 receptor antagonist is dependent on genetic background. Arthritis Rheum. 2005;52(12):3731-3738. (Pubitemid 41798209)
17. Matsuki T, Isoda K, Horai R, et al. Involvement of tumor necrosis factor-α in the development of T cell-dependent aortitis in interleukin-1 receptor antagonist-deficient mice. Circulation. 2005;112(9):1323-1331. (Pubitemid 41266728)
18. Shepherd J, Nicklin MJ. Elastic-vessel arteritis in interleukin-1 receptor antagonist-deficient mice involves effector Th1 cells and requires interleukin-1 receptor. Circulation. 2005;111(23):3135-3140. (Pubitemid 40847792)
19. Horai R, Nakajima A, Habiro K, et al. TNF-α is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin Invest. 2004; 114(11):1603-1611. (Pubitemid 40385551)
20. Shepherd J, Little MC, Nicklin MJ. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol. 2004;122(3):665-669. (Pubitemid 38471334)
21. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A. 2003;100(10):5986-5990. (Pubitemid 36576918)
22. Horai R, Saijo S, Tanioka H, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000;191(2):313-320. (Pubitemid 30060920)
23. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine. 2006;33(2):72-78.
24. Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153(1):66-67.
25. Cooper KD, Hammerberg C, Baadsgaard O, et al. Interleukin-1 in human skin: dysregulation in psoriasis. J Invest Dermatol. 1990;95(5)(suppl):24S-26S.
26. Debets R, Hegmans JP, Croughs P, et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol. 1997; 158(6):2955-2963. (Pubitemid 127470559)
27. Levenson D. New inherited immune disorder revealed. Am J Med Genet A. 2009; 149A(9):fm v-fm vi.
28. Zelickson BD, Muller SA. Generalized pustular psoriasis in childhood: report of thirteen cases. J Am Acad Dermatol. 1991;24(2, pt 1):186-194.
29. Ivker RA, Grin-Jorgensen CM, Vega VK, Hoss DM, Grant-Kels JM. Infantile generalized pustular psoriasis associated with lytic lesions of the bone. Pediatr Dermatol. 1993;10(3):277-282. (Pubitemid 23275302)
30. Prose NS, Fahrner LJ, Miller CR, Layfield L. Pustular psoriasis with chronic recurrent multifocal osteomyelitis and spontaneous fractures. J AmAcad Dermatol. 1994;31(2, pt 2):376-379. (Pubitemid 24249270)